T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Sarah E. Josefsson(Oslo University Hospital), June H. Myklebust(Oslo University Hospital), Daniela Pende(Ospedale Policlinico San Martino), Jonathan M. Irish(Vanderbilt University), Kanutte Huse(Oslo University Hospital), Chloé B. Steen(Stanford University), Ole Christian Lingjærde(Oslo University Hospital), Bjørn Østenstad(Oslo University Hospital), Klaus Beiske(Oslo University Hospital), Ronald Levy(Hôpital Necker-Enfants Malades), Arne Kolstad(Oslo University Hospital), Else Marit Inderberg(Oslo University Hospital), Erlend B. Smeland(Norwegian Cancer Society)
Cited by 95
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k